Thread by @ejustin46

𝗕𝗟𝗢𝗢𝗗 𝗖𝗔𝗡𝗖𝗘𝗥 𝗮𝗻𝗱 𝗖𝗢𝗩𝗜𝗗-19

(Key study !)

"The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. " thelancet.com/journals/eclin…

2) "The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction ...

3) ... in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates."

4) Fig. COVID-19 severity prevalence and mortality rate, overall mortality rate, mortality per malignancy status at COVID-19 onset, and mortality per reason for mortality.

5) Fig. COVID-19 severity prevalence and mortality rate, overall mortality rate, mortality per malignancy status at COVID-19 onset, and mortality per reason for mortality.

6) Fig. Survival probability per diagnosis semester, vaccination status, and COVID-19 treatment. A

7) Fig. Survival probability per diagnosis semester, vaccination status, and COVID-19 treatment.

8) 𝗜𝗡𝗧𝗘𝗥𝗣𝗥𝗘𝗧𝗔𝗧𝗜𝗢𝗡
"Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores ...

9) ... the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis ...

10) ... and prompt treatment in preventing severe COVID-19 cases."

Thanks for reading 🙏